查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1489271

全球格林巴利症候群 (GBS) 市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Guillain-Barre Syndrome (GBS) Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 224 Pages | 商品交期: 最快1-2个工作天内

价格

全球格林巴利症候群（GBS）市场需求预计将从2023年的6.7262亿美元达到2032年近10.5424亿美元的市场规模，2024-2032年研究期间复合年增长率为5.12%。

格林巴利症候群 (GBS) 是一种罕见的自体免疫疾病，免疫系统以周边神经为目标，导致肌肉无力和瘫痪。症状通常始于腿部刺痛和无力，然后可能发展到影响整个身体。感染通常会引发 GBS，需要免疫治疗和物理治疗等药物治疗才能康復。早期诊断和介入对于获得更好的结果至关重要。

市场动态

格林巴利症候群 (GBS) 市场是由影响与该疾病相关的诊断、治疗和研究的各种因素所驱动的。提高医疗保健专业人员和公众对格林巴利综合症 (GBS) 的认识有助于实现早期诊断和干预，这对于更好的患者治疗效果至关重要。 GBS 盛行率不断上升，通常与寨卡病毒以及最近的 COVID-19 等感染有关，这加剧了人们对这种综合征的关注。医学研究和技术进步提高了对 GBS 的了解，从而带来更有效的治疗方法。免疫球蛋白疗法和血浆置换术是 GBS 的主要治疗方法，已经取得了重大进展，提高了其疗效和可近性。

政府和私人对罕见疾病研究的资助也透过促进创新和新的治疗选择来支持 GBS 市场的成长。此外，越来越多的专业医疗机构和先进诊断工具的出现有助于改善 GBS 的管理。医疗保健提供者、研究人员和患者权益团体之间的合作对于提高人们的认识和支持格林巴利症候群 (GBS) 患者、推动市场成长至关重要。然而，某些地区的认识有限和诊断较晚可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对格林-巴利症候群（GBS）全球市场的各个细分市场进行了包容性评估。格林巴利症候群 (GBS) 产业的成长和趋势为本研究提供了整体方法。

市场区隔

格林-巴利综合症 (GBS) 市场报告的这一部分提供了有关国家和区域级别细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按治疗类型

  • 第一线治疗（静脉注射免疫球蛋白 (IVIG)、血浆置换（血浆置换））
  • 支持治疗

按类型

  • 急性发炎性脱髓鞘多发性神经病变 (AIDP)
  • 慢性发炎性脱髓鞘多发性神经根神经病变 (CIDP)
  • 米勒费希尔症候群 (MFS)
  • 急性运动轴突神经病变 (AMAN)
  • 其他类型

按性别

  • 男性
  • 女性

按年龄段

  • 20岁以下
  • 21-40岁
  • 41-59岁
  • 60岁以上

按最终用户

  • 医院
  • 诊所
  • 復健中心
  • 其他最终用户

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲地区格林巴利综合症 (GBS) 市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。格林-巴利综合症(GBS) 市场的主要参与者包括艾伯维公司(AbbVie Inc.)、百健公司(Biogen Inc.)、卡迪拉医疗保健有限公司(Cadila Healthcare Limited)、CSL Behring LLC 、F.Hoffmann-La Roche Ltd.、葛兰素史克公司(GSK Plc)、Grifols SA、LGM Pharmaceuticals Inc.、默克公司、Octapharma AG、辉瑞公司、武田製药有限公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：格林巴利症候群 (GBS) - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按治疗类型进行的市场吸引力分析
    • 按类型分類的市场吸引力分析
    • 按性别分類的市场吸引力分析
    • 按年龄组别分類的市场吸引力分析
    • 最终用户的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球格林巴利症候群 (GBS) 市场分析：依治疗类型

  • 按治疗类型概述
  • 历史和预测数据
  • 依治疗类型分析
  • 第一线治疗（静脉注射免疫球蛋白 (IVIG)、血浆置换（血浆置换））
  • 支持治疗

第 6 章：全球格林巴利症候群 (GBS) 市场分析：按类型

  • 按类型概述
  • 历史和预测数据
  • 按类型分析
  • 急性发炎性脱髓鞘多发性神经病变 (AIDP)
  • 慢性发炎性脱髓鞘多发性神经根神经病变 (CIDP)
  • 米勒费希尔症候群 (MFS)
  • 急性运动轴突神经病变 (AMAN)
  • 其他类型

第 7 章：全球格林巴利症候群 (GBS) 市场分析：依性别

  • 按性别分類的概述
  • 历史和预测数据
  • 按性别分析
  • 男性
  • 女性

第 8 章：全球格林巴利症候群 (GBS) 市场分析：按年龄组别划分

  • 按年龄组别概述
  • 历史和预测数据
  • 按年龄组分析
  • 20岁以下
  • 21-40岁
  • 41-59岁
  • 60岁以上

第 9 章：全球格林巴利症候群 (GBS) 市场分析：依最终用户分类

  • 最终用户概述
  • 历史和预测数据
  • 最终用户分析
  • 医院
  • 诊所
  • 復健中心
  • 其他最终用户

第 10 章：全球格林巴利症候群 (GBS) 市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 11 章：格林巴利症候群 (GBS) 公司的竞争格局

  • 格林巴利症候群（GBS）市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 12 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • AbbVie Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Biogen Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Cadila Healthcare Limited
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • CSL Behring LLC
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • F.Hoffmann-La Roche Ltd.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • GSK Plc
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Grifols SA
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • LGM Pharmaceuticals Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Merck & Co. Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Octapharma AG
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Pfizer Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Takeda Pharmaceutical Company Limited
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR112114696

The global demand for Guillain-Barre Syndrome (GBS) Market is presumed to reach the market size of nearly USD 1054.24 Million by 2032 from USD 672.62 Million in 2023 with a CAGR of 5.12% under the study period 2024-2032.

Guillain-Barre syndrome (GBS) is an uncommon autoimmune disorder in which the immune system targets the peripheral nerves, leading to muscle weakness and paralysis. Symptoms often begin with tingling & weakness in the legs and can progress to affect the entire body. An infection typically triggers GBS and requires medical treatment such as immunotherapy and physical therapy for recovery. Early diagnosis and intervention are vital for better outcomes.

MARKET DYNAMICS

The guillain-barre syndrome (GBS) market is driven by various factors influencing the diagnosis, treatment, and research associated with this condition. Spurring awareness among healthcare professionals and the public about guillain-barre syndrome (GBS)has led to earlier diagnosis and intervention, which is crucial for better patient outcomes. The rising prevalence of GBS, often linked to infections like the Zika virus and, more recently, COVID-19, has heightened the focus on this syndrome. Medical research and technology advances have improved the understanding of GBS, leading to more effective treatments and therapies. Immunoglobulin therapy and plasmapheresis, the primary treatments for GBS, have seen significant advancements, enhancing their efficacy and accessibility.

Government and private funding for rare disease research also supports the growth of the GBS market by fostering innovation and new treatment options. Furthermore, the increasing number of specialized healthcare facilities and the availability of advanced diagnostic tools contribute to the improved management of GBS. Collaborative efforts among healthcare providers, researchers, and patient advocacy groups are vital in driving awareness and supporting those affected by guillain-barre syndrome (GBS), propelling the market growth. However, limited awareness and late diagnosis in certain regions may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Guillain-Barre Syndrome (GBS). The growth and trends of Guillain-Barre Syndrome (GBS) industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Guillain-Barre Syndrome (GBS) market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis))
  • Supportive treatment

By Type

  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Miller Fisher Syndrome (MFS)
  • Acute Motor Axonal Neuropathy (AMAN)
  • Other Types

By Gender

  • Male
  • Female

By Age Group

  • Below 20 years
  • 21-40 years
  • 41-59 years
  • 60 and above

By End-user

  • Hospitals
  • Clinics
  • Rehabilitation Centers
  • Other end-users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Guillain-Barre Syndrome (GBS) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Guillain-Barre Syndrome (GBS) market include AbbVie Inc., Biogen Inc., Cadila Healthcare Limited, CSL Behring LLC, F.Hoffmann-La Roche Ltd., GSK Plc, Grifols SA, LGM Pharmaceuticals Inc., Merck & Co. Inc., Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. GUILLAIN-BARRE SYNDROME (GBS) - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Gender
    • 3.7.4 Market Attractiveness Analysis By Age Group
    • 3.7.5 Market Attractiveness Analysis By End-user
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Treatment Type
  • 5.4. First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Historic and Forecast Sales By Regions
  • 5.5. Supportive treatment Historic and Forecast Sales By Regions

6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TYPE

  • 6.1. Overview By Type
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Type
  • 6.4. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Historic and Forecast Sales By Regions
  • 6.5. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Historic and Forecast Sales By Regions
  • 6.6. Miller Fisher Syndrome (MFS) Historic and Forecast Sales By Regions
  • 6.7. Acute Motor Axonal Neuropathy (AMAN) Historic and Forecast Sales By Regions
  • 6.8. Other Types Historic and Forecast Sales By Regions

7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GENDER

  • 7.1. Overview By Gender
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Gender
  • 7.4. Male Historic and Forecast Sales By Regions
  • 7.5. Female Historic and Forecast Sales By Regions

8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY AGE GROUP

  • 8.1. Overview By Age Group
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Age Group
  • 8.4. Below 20 years Historic and Forecast Sales By Regions
  • 8.5. 21-40 years Historic and Forecast Sales By Regions
  • 8.6. 41-59 years Historic and Forecast Sales By Regions
  • 8.7. 60 and above Historic and Forecast Sales By Regions

9. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY END-USER

  • 9.1. Overview By End-user
  • 9.2. Historical and Forecast Data
  • 9.3. Analysis By End-user
  • 9.4. Hospitals Historic and Forecast Sales By Regions
  • 9.5. Clinics Historic and Forecast Sales By Regions
  • 9.6. Rehabilitation Centers Historic and Forecast Sales By Regions
  • 9.7. Other end-users Historic and Forecast Sales By Regions

10. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE GUILLAIN-BARRE SYNDROME (GBS) COMPANIES

  • 11.1. Guillain-Barre Syndrome (GBS) Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. AbbVie Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Biogen Inc.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Cadila Healthcare Limited
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. CSL Behring LLC
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. F.Hoffmann-La Roche Ltd.
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. GSK Plc
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Grifols SA
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. LGM Pharmaceuticals Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. Merck & Co. Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Octapharma AG
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments
  • 12.13. Pfizer Inc.
    • 12.13.1 Company Overview
    • 12.13.2 Company Revenue
    • 12.13.3 Products
    • 12.13.4 Recent Developments
  • 12.14. Takeda Pharmaceutical Company Limited
    • 12.14.1 Company Overview
    • 12.14.2 Company Revenue
    • 12.14.3 Products
    • 12.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Market Sales By Geography (USD MN)
  • Supportive treatment Market Sales By Geography (USD MN)
  • Analysis By Type (USD MN)
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Sales By Geography (USD MN)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Sales By Geography (USD MN)
  • Miller Fisher Syndrome (MFS) Market Sales By Geography (USD MN)
  • Acute Motor Axonal Neuropathy (AMAN) Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Analysis By Gender (USD MN)
  • Male Market Sales By Geography (USD MN)
  • Female Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Below 20 years Market Sales By Geography (USD MN)
  • 21-40 years Market Sales By Geography (USD MN)
  • 41-59 years Market Sales By Geography (USD MN)
  • 60 and above Market Sales By Geography (USD MN)
  • Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Rehabilitation Centers Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Guillain-Barre Syndrome (GBS) Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Guillain-Barre Syndrome (GBS) Report
  • Market Research Process
  • Market Research Methodology
  • Global Guillain-Barre Syndrome (GBS) Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Gender
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-user
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Market Sales By Geography (USD MN)
  • Supportive treatment Market Sales By Geography (USD MN)
  • Global Market Analysis By Type (USD MN)
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Sales By Geography (USD MN)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Sales By Geography (USD MN)
  • Miller Fisher Syndrome (MFS) Market Sales By Geography (USD MN)
  • Acute Motor Axonal Neuropathy (AMAN) Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Gender (USD MN)
  • Male Market Sales By Geography (USD MN)
  • Female Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Below 20 years Market Sales By Geography (USD MN)
  • 21-40 years Market Sales By Geography (USD MN)
  • 41-59 years Market Sales By Geography (USD MN)
  • 60 and above Market Sales By Geography (USD MN)
  • Global Market Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Rehabilitation Centers Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.